Brief: Inozyme Pharma Receives Orphan Drug Designation For Inz-701 From The European Medicines Agency For The Treatment Of Abcc6 Deficiency

Inozyme Pharma

21/07/2021 12:35

July 21 (Reuters) - Inozyme Pharma Inc  INZY.O :
    * INOZYME PHARMA RECEIVES ORPHAN DRUG DESIGNATION FOR
INZ-701 FROM
THE EUROPEAN MEDICINES AGENCY FOR THE TREATMENT OF ABCC6
DEFICIENCY
    * INOZYME - PREPARING TO INITIATE A PHASE 1/2 CLINICAL TRIAL
IN
PATIENTS WITH ENPP1 DEFICIENCY IN MID 2021
    * INOZYME PHARMA INC - PREPARING TO INITIATE A SEPARATE
PHASE 1/2
CLINICAL TRIAL IN PATIENTS WITH ABCC6 DEFICIENCY IN MID-2021

Source text for Eikon:  ID:nGNX9hgddt 
Further company coverage:  INZY.O 

 ((Reuters.Briefs@thomsonreuters.com;))